FDA-Approved Carnexiv Provides New Option for Certain Epilepsy Patients
The Food and Drug Administration (FDA) has approved Carnexiv (carbamazepine; Lundbeck) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible.
Carnexiv, an antiepileptic drug, is a short-term (≤7 days) intravenous (IV) replacement therapy for oral carbamazepine formulations in adults with the following seizure types:
- Partial seizures with complex symptomatology
- Generalized tonic-clonic seizures
- Mixed seizure patterns which include the above, or other partial or generalized seizures
At the end of the IV replacement period, patients should be switched back to their previous oral carbamazepine total daily dose and frequency as soon as clinically appropriate.
The mechanism by which carbamazepine exerts its anticonvulsant activity is unknown.
The FDA granted Carnexiv orphan drug designation as it is the first available IV formulation of carbamazepine. It is expected to be available in the United States in early 2017.
Carnexiv is supplied as a 200mg/20mL solution in single-dose vials.
For more information visit Lundbeck.com.